BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b) On March 17, 2017, Secretary Togo D. West, Jr. notified Bristol-Myers Squibb Company that he will not stand for re-election to the Board of Directors at the 2017 Annual Meeting of Shareholders, which is expected to be held on May 2, 2017.
About BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP)
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac. BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Recent Trading Information
BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) closed its last trading session 00.00 at 1,050.00 with shares trading hands.
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac. BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Recent Trading Information
BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) closed its last trading session 00.00 at 1,050.00 with shares trading hands.
